FDA Approves First-Ever Gene Therapy for Inherited Hearing Loss
Regeneron has received FDA approval for Otarmeni, the first gene therapy ever cleared to treat an inherited form of hearing loss. This marks a landmark moment in gene therapy, offering a potential one-time treatment for patients born with a specific genetic mutation causing deafness or severe hearing impairment. Unlike hearing aids or cochlear implants, which compensate for hearing loss, gene therapy aims to address the underlying genetic defect. While the article is paywalled and full clinical details are limited, the approval signals growing momentum in using gene-based tools to treat sensory and neurological conditions. For health-conscious adults, this represents a broader trend of precision medicine expanding into areas once considered untreatable, with implications for aging-related hearing decline research down the road.